Zoetis [ZTS] vs Neurocrine [NBIX] Detailed Stock Comparison

Zoetis

NYSE
Loading...

Neurocrine

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Zoetis wins in 10 metrics, Neurocrine wins in 9 metrics, with 0 ties. Zoetis appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricZoetisNeurocrineBetter
P/E Ratio (TTM)24.6841.02Zoetis
Price-to-Book Ratio12.775.03Neurocrine
Debt-to-Equity Ratio137.0118.18Neurocrine
PEG Ratio1.410.58Neurocrine
EV/EBITDA17.3825.47Zoetis
Profit Margin (TTM)27.83%13.88%Zoetis
Operating Margin (TTM)40.20%21.18%Zoetis
EBITDA Margin (TTM)40.20%21.18%Zoetis
Return on Equity52.77%13.39%Zoetis
Return on Assets (TTM)15.37%8.67%Zoetis
Free Cash Flow (TTM)$2.30B$557.20MZoetis
Dividend Yield1.11%N/AN/A
1-Year Return-26.34%19.95%Neurocrine
Price-to-Sales Ratio (TTM)6.765.48Neurocrine
Enterprise Value$68.57B$13.44BZoetis
EV/Revenue Ratio7.315.35Neurocrine
Gross Profit Margin (TTM)73.62%98.36%Neurocrine
Revenue per Share (TTM)$21$25Neurocrine
Earnings per Share (Diluted)$5.80$3.34Zoetis
Beta (Stock Volatility)0.890.28Neurocrine
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Zoetis vs Neurocrine Stock Performance Analysis

Loading Price Chart...

Zoetis
Neurocrine
Zoetis Stock Overview | Neurocrine Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Zoetis1.51%-1.63%-7.29%-7.89%-11.87%-11.75%
Neurocrine-0.19%-2.95%-3.65%5.67%26.25%-0.81%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Zoetis-26.34%-3.23%-12.26%233.57%362.75%362.75%
Neurocrine19.95%26.32%30.95%196.62%1,762.94%196.94%

News Based Sentiment: Zoetis vs Neurocrine

Zoetis

News based Sentiment: MIXED

The month featured both positive developments – the CVMP opinion for Portela® and generally positive analyst estimates – alongside negative signals like stock decline, technical warnings, and mixed institutional activity. This creates a balanced, rather than decisively positive or negative, investment narrative.

View Zoetis News Sentiment Analysis

Neurocrine

News based Sentiment: POSITIVE

Neurocrine Biosciences delivered a strong Q2 performance, exceeding revenue and EPS estimates, and presented positive Phase 2 data for osavampator. While insider selling is a concern, growing institutional investment and positive analyst coverage suggest continued optimism about the company's future prospects.

View Neurocrine News Sentiment Analysis

Performance & Financial Health Analysis: Zoetis vs Neurocrine

MetricZTSNBIX
Market Information
Market Cap i$63.73B$13.75B
Market Cap CategoryN/ALarge cap
10 Day Avg. Volume i2,724,6071,023,952
90 Day Avg. Volume i2,517,512832,457
Last Close$167.10$136.74
52 Week Range$139.70 - $200.33$84.23 - $154.61
% from 52W High-16.59%-11.56%
All-Time High$249.27 (Dec 27, 2021)$157.98 (Jul 29, 2024)
% from All-Time High-32.96%-13.44%
Growth Metrics
Quarterly Revenue Growth0.04%0.17%
Quarterly Earnings Growth0.15%0.65%
Financial Health
Profit Margin (TTM) i0.28%0.14%
Operating Margin (TTM) i0.40%0.21%
Return on Equity (TTM) i0.53%0.13%
Debt to Equity (MRQ) i137.0118.18
Cash & Liquidity
Book Value per Share (MRQ)$11.21$27.22
Cash per Share (MRQ)$3.28$9.84
Operating Cash Flow (TTM) i$2.93B$567.30M
Levered Free Cash Flow (TTM) i$2.29B$367.04M
Dividends
Last 12-Month Dividend Yield i1.11%N/A
Last 12-Month Dividend i$1.86N/A

Valuation & Enterprise Metrics Analysis: Zoetis vs Neurocrine

MetricZTSNBIX
Price Ratios
P/E Ratio (TTM) i24.6841.02
Forward P/E i22.5722.06
PEG Ratio i1.410.58
Price to Sales (TTM) i6.765.48
Price to Book (MRQ) i12.775.03
Market Capitalization
Market Capitalization i$63.73B$13.75B
Enterprise Value i$68.57B$13.44B
Enterprise Value Metrics
Enterprise to Revenue i7.315.35
Enterprise to EBITDA i17.3825.47
Risk & Other Metrics
Beta i0.890.28
Book Value per Share (MRQ) i$11.21$27.22

Financial Statements Comparison: Zoetis vs Neurocrine

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)ZTSNBIX
Revenue/Sales i$2.22B$572.60M
Cost of Goods Sold i$622.00M$9.20M
Gross Profit i$1.60B$563.40M
Research & Development i$157.00M$263.20M
Operating Income (EBIT) i$846.00M$23.70M
EBITDA i$991.00M$40.30M
Pre-Tax Income i$810.00M$14.70M
Income Tax i$179.00M$6.80M
Net Income (Profit) i$631.00M$7.90M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)ZTSNBIX
Cash & Equivalents i$1.72B$194.10M
Total Current Assets i$5.88B$1.64B
Total Current Liabilities i$3.39B$522.90M
Long-Term Debt i$5.40B$447.50M
Total Shareholders Equity i$4.66B$2.54B
Retained Earnings i$12.38B$-5.30M
Property, Plant & Equipment i$6.36B$589.20M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)ZTSNBIX
Operating Cash Flow i$567.00M$21.80M
Capital Expenditures iN/AN/A
Free Cash Flow i$438.00M$54.10M
Debt Repayment iN/AN/A
Common Stock Repurchase i$-443.00M$-150.00M

Short Interest & Institutional Ownership Analysis

MetricZTSNBIX
Shares Short i7.76M4.12M
Short Ratio i2.405.71
Short % of Float i0.02%0.06%
Average Daily Volume (10 Day) i2,724,6071,023,952
Average Daily Volume (90 Day) i2,517,512832,457
Shares Outstanding i448.47M99.40M
Float Shares i442.31M98.01M
% Held by Insiders i0.00%0.01%
% Held by Institutions i0.99%1.02%

Dividend Analysis & Yield Comparison: Zoetis vs Neurocrine

MetricZTSNBIX
Last 12-Month Dividend i$1.86N/A
Last 12-Month Dividend Yield i1.11%N/A
3-Year Avg Annual Dividend i$1.63N/A
3-Year Avg Dividend Yield i0.24%N/A
3-Year Total Dividends i$4.90N/A
Ex-Dividend DateApr 21, 2025N/A